The impact of androgen ablation therapy on cognition in*

描述(由申请人提供)： 前列腺癌是美国男性最常见的癌症部位，2004年有超过23万男性被诊断为前列腺癌。这种疾病通常影响老年人；所有新病例的70%发生在65岁以上的男性中。雄激素消融治疗是晚期前列腺癌的标准治疗方法。对于患有晚期疾病的男性，接受这种治疗的中位时间从2年到5年不等。这种疗法对生活质量的影响已经有了很好的记录；然而，这种疗法对认知功能的影响还没有完全阐明。认知功能对独立性和生产力至关重要。直到最近，研究人员才发表了关于雄激素消融治疗对认知影响的研究。尽管这些研究提供了有价值的初步结果，表明雄激素消融可能会对记忆、视觉空间能力、精神运动速度和执行功能产生不利影响，但这些研究的数量有限，并未产生一致的结果。这些研究的重点是只接受雄激素消融治疗6到12个月的男性，然而大多数晚期前列腺癌患者将继续接受雄激素消融治疗2年以上。此外，这些研究并没有特别关注65岁及以上的患者，这是最常见的前列腺癌患者。 这项建议试图通过进行一项比较研究来解决文献中的这些空白，该研究将75名65岁及以上接受雄激素消融治疗的晚期前列腺癌患者的认知功能与75名尚未开始雄激素消融治疗的晚期前列腺癌患者的认知功能进行比较。这项研究的具体目的是： 1.确定接受雄激素消融治疗2年的65岁以上男性的认知功能损害范围。 2.确定接受雄激素消融治疗2年的65岁以上男性认知功能障碍的严重程度。

DESCRIPTION (provided by applicant): Prostate cancer is the most common site of cancer in men in the United States with over 230,000 men diagnosed with prostate cancer in 2004. This disease generally impacts older adults; 70% of all new cases occur in men greater than 65 years of age. Androgen ablation therapy is the standard treatment for advanced prostate cancer. For men with advanced stage disease, the median length of time on this treatment ranges from 2 to 5 years. The quality of life implications of this therapy have been well documented; however the impact of this treatment on cognitive functioning has not been fully elucidated. Cognitive functioning is vital for independence and productivity. Only recently have researchers published studies focusing on the cognitive impact of androgen ablation therapy. Although these studies have provided valuable preliminary results suggesting that androgen ablation may adversely affect memory, visuospatial abilities, psychomotor speed, and executive functioning, these studies are limited in number and have not produced consistent findings. These studies have focused on men who have been receiving androgen ablation therapy for only 6 to 12 months, however most men with advance stage prostate cancer will continue on androgen ablation for over 2 years. Additionally, these studies have not specifically focused on patients age 65 and older, the population most commonly afflicted with prostate cancer. This proposal seeks to address these gaps in the literature by conducting a comparison study that will compare the cognitive functioning of 75 men with late stage prostate cancer age 65 and older who have received androgen ablation therapy for 2 years to the cognitive functioning of 75 men with late stage prostate cancer who have not yet started androgen ablation therapy. The specific aims of this study are: 1. To determine the domains of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years. 2. To determine the severity of cognitive impairment in men over the age of 65 who have received androgen ablation therapy for 2 years.